• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nucleic Acid Therapeutics >Human RGM249-Derived Small RNAs Potentially Regulate Tumor Malignancy
【24h】

Human RGM249-Derived Small RNAs Potentially Regulate Tumor Malignancy

机译：人类RGM249衍生的小RNA可能调节肿瘤恶性肿瘤

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The human noncoding RNA gene RGM249 has been shown to regulate the degree of cancer cell differentiation. In this study, we investigated the effects of 3 microRNA-like molecules digested from RGM249 on the loss of malignant properties in cancer cellsin immunodeficient KSN/Slc mice. We utilized small interfering RNAs (siRNAs) alone or in combination with a cationized drug delivery system (DDS) consisting of atelocollagen or gelatin hydrogel microspheres. The results demonstrated growth inhibition andapoptosis and the inhibition of both neovascularization and metastasis, indicating that the DDSs effectively infiltrated the majority of tumor cells in vivo. Systemic administration of the 3 siRNAs inhibited the metastatic ability of malignant cells. Co-transfection of these siRNAs exerted a regulatory effect upon the genes involved in differentiation, pluripotency, and proliferation in cancer cells. These results suggest that RGM249-derived oligonucleotides may be involved in the regulation of metastasis, proliferation, and differentiation in vivo, and that the tested siRNAs may therefore represent a new anticancer therapeutic approach.
机译：已显示人非划分的RNA基因RGM249调节癌细胞分化程度。在这项研究中，我们研究了从RGM249消化的3 microRNA样子对癌细胞蛋白免疫缺失KSN / SLC小鼠的恶性性质丧失的影响。我们使用小干扰RNA（siRNA）单独或与阳离子化的药物递送系统（DDS）组合，包括Etelocollagen或明胶水凝胶微球。结果证明了生长抑制胃病和新生血管形成和转移的抑制，表明DDSS有效地渗透了体内大多数肿瘤细胞。 3 siRNA的全身施用抑制恶性细胞的转移能力。这些siRNA的共转染对癌细胞中涉及分化，多能性和增殖的基因产生了调节作用。这些结果表明RGM249衍生的寡核苷酸可参与体内转移，增殖和分化的调节，并且所测试的SIRNA可以代表一种新的抗癌治疗方法。

著录项

  • 来源
    《Nucleic Acid Therapeutics》 |2013年第5期|共12页
  • 作者

    Norimasa Miura; Mika Shimizu; Waka Shinoda; Satoshi Tsuno; Reina Sato; Xinhui Wang; Jun-ichiro Jo; Yasuhiko Tabata; Junichi Hasegawa;

  • 作者单位

    Division of Pharmacotherapeutics Department of Pathophysiological and Therapeutic Science Faculty of Medicine Tottori University Yonago Tottori Japan;

    Division of Pharmacotherapeutics Department of Pathophysiological and Therapeutic Science Faculty of Medicine Tottori University Yonago Tottori Japan;

    Division of Pharmacotherapeutics Department of Pathophysiological and Therapeutic Science Faculty of Medicine Tottori University Yonago Tottori Japan;

    Division of Pharmacotherapeutics Department of Pathophysiological and Therapeutic Science Faculty of Medicine Tottori University Yonago Tottori Japan;

    Division of Pharmacotherapeutics Department of Pathophysiological and Therapeutic Science Faculty of Medicine Tottori University Yonago Tottori Japan;

    Division of Pharmacotherapeutics Department of Pathophysiological and Therapeutic Science Faculty of Medicine Tottori University Yonago Tottori Japan;

    Department of Biomaterials Field of Tissue Engineering Institute forFrontier Medical Sciences Kyoto University Kyoto Japan;

    Department of Biomaterials Field of Tissue Engineering Institute for Frontier Medical Sciences Kyoto University Kyoto Japan;

    Division of Pharmacotherapeutics Department of Pathophysiological and Therapeutic Science Faculty of Medicine Tottori University Yonago Tottori Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 生物化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号